Global Mumps Vaccine Market

Mumps Vaccine Comprehensive Study by Type (Mono Vaccines, Combination Vaccines, Others), Distribution Channel (Hospitals Pharmacies, Drug Stores, Retail Pharmacies, Others), End User (Hospital, Pediatric Clinic, Pharmacy, NGOS, Others), Diseases (Measles, Mumps, Rubella) Players and Region - Global Market Outlook to 2027

Mumps Vaccine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Mumps Vaccine
Mumps vaccine are type of vaccine which prevent the mumps. When given to a majority of the population they decrease complications at the population level. Two doses are required for long term prevention from mumps. Mumps vaccine is the best way to decrease your child’s risk of getting mumps. It is usually given as part of a combination vaccine that protects against three diseases: measles, mumps, and rubella. The first dosage of the MMR vaccine is given to babies between ages of 12 and 15 months while the second dose is given between ages of 3 and 4 years. Mumps vaccine are a mixture of live viruses that are injected. The live viruses are inactivated and cannot reproduce in human cells while the immune system responds and defends against the infection.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The companies are researching the market by utilizing their preferred strategies, which include mergers and acquisitions, expansions, investments, the launch of new services, and collaborations. Through expansions and acquisitions, the players are examining new geographies in an effort to compete through efficiencies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Mumps Vaccine market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

MedImmune (United States), Johnson & Johnson (United States), Merck & Co., Inc. (United States), Sanofi (France), Serum institute (India), Bavarian Nordic (Denmark), Astellas Pharma (India), CSL Limited (Australia), Emergent BioSolutions (United States) and GlaxoSmithKline (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Panacea Biotec, Ltd. (India), Biological E Limited (India), Bharat Biotech Ltd. (India) and Novavax, Inc (United States).

Segmentation Overview
AMA Research has segmented the market of Global Mumps Vaccine market by Type (Mono Vaccines, Combination Vaccines and Others) and Region.



On the basis of geography, the market of Mumps Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel , the sub-segment i.e. Hospitals Pharmacies will boost the Mumps Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital will boost the Mumps Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diseases, the sub-segment i.e. Measles will boost the Mumps Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
In 19 may 2022 CCC completed the merge and acquisition with Biocon NA SERUME institute.
On 6 June 2022 Priorix has been approved by the US FDA to prevent measles, mumps, and rubella in people 12 months of age and older, according to GSK. Priorix become an additional to measles, mumps, and rubella. Priorix providers to assist patients in protecting themselves from these contagious diseases, and to further enhance our pediatric vaccine offerings.


Market Drivers
  • Increases Number Of The Rates And Occurrence Diseases
  • Growing Awareness About Vaccination In Consumer
  • The Rise In The Number Of Cases And The Prevalence Of Measles, Mumps, And Rubella

Opportunities
  • High Growth Vision In Emerging Market

Restraints
  • A High Cost Of Vaccination Development
  • A Lack Of Information About Vaccination In Rural Area
  • Low Vaccination Availability In Rural Areas

Challenges
  • Inequitable Access To Vaccines
  • High Prices Of Mumps Vaccine Combination In Market


Key Target Audience
Mumps Vaccine Manufactures, New Participants and Investors, Mumps Vaccine Distributors and Suppliers, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Mono Vaccines
  • Combination Vaccines
  • Others
By Distribution Channel
  • Hospitals Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Others

By End User
  • Hospital
  • Pediatric Clinic
  • Pharmacy
  • NGOS
  • Others

By Diseases
  • Measles
  • Mumps
  • Rubella

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increases Number Of The Rates And Occurrence Diseases
      • 3.2.2. Growing Awareness About Vaccination In Consumer
      • 3.2.3. The Rise In The Number Of Cases And The Prevalence Of Measles, Mumps, And Rubella
    • 3.3. Market Challenges
      • 3.3.1. Inequitable Access To Vaccines
      • 3.3.2. High Prices Of Mumps Vaccine Combination In Market
    • 3.4. Market Trends
      • 3.4.1. New Product Launches To Flourish Mumps Vaccine Market
      • 3.4.2. Growing Supply Of The Product By WHO
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Mumps Vaccine, by Type, Distribution Channel , End User, Diseases and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Mumps Vaccine (Value)
      • 5.2.1. Global Mumps Vaccine by: Type (Value)
        • 5.2.1.1. Mono Vaccines
        • 5.2.1.2. Combination Vaccines
        • 5.2.1.3. Others
      • 5.2.2. Global Mumps Vaccine by: End User (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Pediatric Clinic
        • 5.2.2.3. Pharmacy
        • 5.2.2.4. NGOS
        • 5.2.2.5. Others
      • 5.2.3. Global Mumps Vaccine by: Diseases (Value)
        • 5.2.3.1. Measles
        • 5.2.3.2. Mumps
        • 5.2.3.3. Rubella
      • 5.2.4. Global Mumps Vaccine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Mumps Vaccine (Price)
      • 5.3.1. Global Mumps Vaccine by: Type (Price)
  • 6. Mumps Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. MedImmune (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co., Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Serum institute (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bavarian Nordic (Denmark)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Astellas Pharma (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. CSL Limited (Australia)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Emergent BioSolutions (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Mumps Vaccine Sale, by Type, Distribution Channel , End User, Diseases and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Mumps Vaccine (Value)
      • 7.2.1. Global Mumps Vaccine by: Type (Value)
        • 7.2.1.1. Mono Vaccines
        • 7.2.1.2. Combination Vaccines
        • 7.2.1.3. Others
      • 7.2.2. Global Mumps Vaccine by: End User (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Pediatric Clinic
        • 7.2.2.3. Pharmacy
        • 7.2.2.4. NGOS
        • 7.2.2.5. Others
      • 7.2.3. Global Mumps Vaccine by: Diseases (Value)
        • 7.2.3.1. Measles
        • 7.2.3.2. Mumps
        • 7.2.3.3. Rubella
      • 7.2.4. Global Mumps Vaccine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Mumps Vaccine (Price)
      • 7.3.1. Global Mumps Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Mumps Vaccine: by Type(USD Million)
  • Table 2. Mumps Vaccine Mono Vaccines , by Region USD Million (2016-2021)
  • Table 3. Mumps Vaccine Combination Vaccines , by Region USD Million (2016-2021)
  • Table 4. Mumps Vaccine Others , by Region USD Million (2016-2021)
  • Table 5. Mumps Vaccine: by End User(USD Million)
  • Table 6. Mumps Vaccine Hospital , by Region USD Million (2016-2021)
  • Table 7. Mumps Vaccine Pediatric Clinic , by Region USD Million (2016-2021)
  • Table 8. Mumps Vaccine Pharmacy , by Region USD Million (2016-2021)
  • Table 9. Mumps Vaccine NGOS , by Region USD Million (2016-2021)
  • Table 10. Mumps Vaccine Others , by Region USD Million (2016-2021)
  • Table 11. Mumps Vaccine: by Diseases(USD Million)
  • Table 12. Mumps Vaccine Measles , by Region USD Million (2016-2021)
  • Table 13. Mumps Vaccine Mumps , by Region USD Million (2016-2021)
  • Table 14. Mumps Vaccine Rubella , by Region USD Million (2016-2021)
  • Table 15. South America Mumps Vaccine, by Country USD Million (2016-2021)
  • Table 16. South America Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 17. South America Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 18. South America Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 19. South America Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 20. Brazil Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 21. Brazil Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 22. Brazil Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 23. Brazil Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 24. Argentina Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 25. Argentina Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 26. Argentina Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 27. Argentina Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 28. Rest of South America Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 29. Rest of South America Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 30. Rest of South America Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 31. Rest of South America Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 32. Asia Pacific Mumps Vaccine, by Country USD Million (2016-2021)
  • Table 33. Asia Pacific Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 34. Asia Pacific Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 35. Asia Pacific Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 36. Asia Pacific Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 37. China Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 38. China Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 39. China Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 40. China Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 41. Japan Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 42. Japan Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 43. Japan Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 44. Japan Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 45. India Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 46. India Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 47. India Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 48. India Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 49. South Korea Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 50. South Korea Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 51. South Korea Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 52. South Korea Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 53. Taiwan Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 54. Taiwan Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 55. Taiwan Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 56. Taiwan Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 57. Australia Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 58. Australia Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 59. Australia Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 60. Australia Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 61. Rest of Asia-Pacific Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 62. Rest of Asia-Pacific Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 63. Rest of Asia-Pacific Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 65. Europe Mumps Vaccine, by Country USD Million (2016-2021)
  • Table 66. Europe Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 67. Europe Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 68. Europe Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 69. Europe Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 70. Germany Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 71. Germany Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 72. Germany Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 73. Germany Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 74. France Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 75. France Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 76. France Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 77. France Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 78. Italy Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 79. Italy Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 80. Italy Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 81. Italy Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 82. United Kingdom Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 83. United Kingdom Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 84. United Kingdom Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 85. United Kingdom Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 86. Netherlands Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 87. Netherlands Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 88. Netherlands Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 89. Netherlands Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 90. Rest of Europe Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 91. Rest of Europe Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 92. Rest of Europe Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 93. Rest of Europe Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 94. MEA Mumps Vaccine, by Country USD Million (2016-2021)
  • Table 95. MEA Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 96. MEA Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 97. MEA Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 98. MEA Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 99. Middle East Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 100. Middle East Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 101. Middle East Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 102. Middle East Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 103. Africa Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 104. Africa Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 105. Africa Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 106. Africa Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 107. North America Mumps Vaccine, by Country USD Million (2016-2021)
  • Table 108. North America Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 109. North America Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 110. North America Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 111. North America Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 112. United States Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 113. United States Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 114. United States Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 115. United States Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 116. Canada Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 117. Canada Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 118. Canada Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 119. Canada Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 120. Mexico Mumps Vaccine, by Type USD Million (2016-2021)
  • Table 121. Mexico Mumps Vaccine, by Distribution Channel USD Million (2016-2021)
  • Table 122. Mexico Mumps Vaccine, by End User USD Million (2016-2021)
  • Table 123. Mexico Mumps Vaccine, by Diseases USD Million (2016-2021)
  • Table 124. Mumps Vaccine: by Type(USD/Units)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Mumps Vaccine: by Type(USD Million)
  • Table 136. Mumps Vaccine Mono Vaccines , by Region USD Million (2022-2027)
  • Table 137. Mumps Vaccine Combination Vaccines , by Region USD Million (2022-2027)
  • Table 138. Mumps Vaccine Others , by Region USD Million (2022-2027)
  • Table 139. Mumps Vaccine: by End User(USD Million)
  • Table 140. Mumps Vaccine Hospital , by Region USD Million (2022-2027)
  • Table 141. Mumps Vaccine Pediatric Clinic , by Region USD Million (2022-2027)
  • Table 142. Mumps Vaccine Pharmacy , by Region USD Million (2022-2027)
  • Table 143. Mumps Vaccine NGOS , by Region USD Million (2022-2027)
  • Table 144. Mumps Vaccine Others , by Region USD Million (2022-2027)
  • Table 145. Mumps Vaccine: by Diseases(USD Million)
  • Table 146. Mumps Vaccine Measles , by Region USD Million (2022-2027)
  • Table 147. Mumps Vaccine Mumps , by Region USD Million (2022-2027)
  • Table 148. Mumps Vaccine Rubella , by Region USD Million (2022-2027)
  • Table 149. South America Mumps Vaccine, by Country USD Million (2022-2027)
  • Table 150. South America Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 151. South America Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 152. South America Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 153. South America Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 154. Brazil Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 155. Brazil Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 156. Brazil Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 157. Brazil Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 158. Argentina Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 159. Argentina Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 160. Argentina Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 161. Argentina Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 162. Rest of South America Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 163. Rest of South America Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 164. Rest of South America Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 165. Rest of South America Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 166. Asia Pacific Mumps Vaccine, by Country USD Million (2022-2027)
  • Table 167. Asia Pacific Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 168. Asia Pacific Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 169. Asia Pacific Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 170. Asia Pacific Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 171. China Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 172. China Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 173. China Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 174. China Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 175. Japan Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 176. Japan Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 177. Japan Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 178. Japan Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 179. India Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 180. India Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 181. India Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 182. India Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 183. South Korea Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 184. South Korea Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 185. South Korea Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 186. South Korea Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 187. Taiwan Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 188. Taiwan Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 189. Taiwan Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 190. Taiwan Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 191. Australia Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 192. Australia Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 193. Australia Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 194. Australia Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 195. Rest of Asia-Pacific Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 196. Rest of Asia-Pacific Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 197. Rest of Asia-Pacific Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 198. Rest of Asia-Pacific Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 199. Europe Mumps Vaccine, by Country USD Million (2022-2027)
  • Table 200. Europe Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 201. Europe Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 202. Europe Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 203. Europe Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 204. Germany Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 205. Germany Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 206. Germany Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 207. Germany Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 208. France Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 209. France Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 210. France Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 211. France Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 212. Italy Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 213. Italy Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 214. Italy Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 215. Italy Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 216. United Kingdom Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 217. United Kingdom Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 218. United Kingdom Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 219. United Kingdom Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 220. Netherlands Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 221. Netherlands Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 222. Netherlands Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 223. Netherlands Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 224. Rest of Europe Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 225. Rest of Europe Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 226. Rest of Europe Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 227. Rest of Europe Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 228. MEA Mumps Vaccine, by Country USD Million (2022-2027)
  • Table 229. MEA Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 230. MEA Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 231. MEA Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 232. MEA Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 233. Middle East Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 234. Middle East Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 235. Middle East Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 236. Middle East Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 237. Africa Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 238. Africa Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 239. Africa Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 240. Africa Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 241. North America Mumps Vaccine, by Country USD Million (2022-2027)
  • Table 242. North America Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 243. North America Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 244. North America Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 245. North America Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 246. United States Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 247. United States Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 248. United States Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 249. United States Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 250. Canada Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 251. Canada Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 252. Canada Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 253. Canada Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 254. Mexico Mumps Vaccine, by Type USD Million (2022-2027)
  • Table 255. Mexico Mumps Vaccine, by Distribution Channel USD Million (2022-2027)
  • Table 256. Mexico Mumps Vaccine, by End User USD Million (2022-2027)
  • Table 257. Mexico Mumps Vaccine, by Diseases USD Million (2022-2027)
  • Table 258. Mumps Vaccine: by Type(USD/Units)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Mumps Vaccine: by Type USD Million (2016-2021)
  • Figure 5. Global Mumps Vaccine: by End User USD Million (2016-2021)
  • Figure 6. Global Mumps Vaccine: by Diseases USD Million (2016-2021)
  • Figure 7. South America Mumps Vaccine Share (%), by Country
  • Figure 8. Asia Pacific Mumps Vaccine Share (%), by Country
  • Figure 9. Europe Mumps Vaccine Share (%), by Country
  • Figure 10. MEA Mumps Vaccine Share (%), by Country
  • Figure 11. North America Mumps Vaccine Share (%), by Country
  • Figure 12. Global Mumps Vaccine: by Type USD/Units (2016-2021)
  • Figure 13. Global Mumps Vaccine share by Players 2021 (%)
  • Figure 14. Global Mumps Vaccine share by Players (Top 3) 2021(%)
  • Figure 15. Global Mumps Vaccine share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. MedImmune (United States) Revenue, Net Income and Gross profit
  • Figure 18. MedImmune (United States) Revenue: by Geography 2021
  • Figure 19. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 20. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 21. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck & Co., Inc. (United States) Revenue: by Geography 2021
  • Figure 23. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 24. Sanofi (France) Revenue: by Geography 2021
  • Figure 25. Serum institute (India) Revenue, Net Income and Gross profit
  • Figure 26. Serum institute (India) Revenue: by Geography 2021
  • Figure 27. Bavarian Nordic (Denmark) Revenue, Net Income and Gross profit
  • Figure 28. Bavarian Nordic (Denmark) Revenue: by Geography 2021
  • Figure 29. Astellas Pharma (India) Revenue, Net Income and Gross profit
  • Figure 30. Astellas Pharma (India) Revenue: by Geography 2021
  • Figure 31. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 32. CSL Limited (Australia) Revenue: by Geography 2021
  • Figure 33. Emergent BioSolutions (United States) Revenue, Net Income and Gross profit
  • Figure 34. Emergent BioSolutions (United States) Revenue: by Geography 2021
  • Figure 35. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2021
  • Figure 37. Global Mumps Vaccine: by Type USD Million (2022-2027)
  • Figure 38. Global Mumps Vaccine: by End User USD Million (2022-2027)
  • Figure 39. Global Mumps Vaccine: by Diseases USD Million (2022-2027)
  • Figure 40. South America Mumps Vaccine Share (%), by Country
  • Figure 41. Asia Pacific Mumps Vaccine Share (%), by Country
  • Figure 42. Europe Mumps Vaccine Share (%), by Country
  • Figure 43. MEA Mumps Vaccine Share (%), by Country
  • Figure 44. North America Mumps Vaccine Share (%), by Country
  • Figure 45. Global Mumps Vaccine: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • MedImmune (United States)
  • Johnson & Johnson (United States)
  • Merck & Co., Inc. (United States)
  • Sanofi (France)
  • Serum institute (India)
  • Bavarian Nordic (Denmark)
  • Astellas Pharma (India)
  • CSL Limited (Australia)
  • Emergent BioSolutions (United States)
  • GlaxoSmithKline (United Kingdom)
Additional players considered in the study are as follows:
Panacea Biotec, Ltd. (India) , Biological E Limited (India) , Bharat Biotech Ltd. (India) , Novavax, Inc (United States)
Select User Access Type

Key Highlights of Report


Jul 2022 246 Pages 55 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Mumps Vaccine Market Quantitative research analysis
Global Mumps Vaccine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as MedImmune (United States), Johnson & Johnson (United States), Merck & Co., Inc. (United States), Sanofi (France), Serum institute (India), Bavarian Nordic (Denmark), Astellas Pharma (India), CSL Limited (Australia), Emergent BioSolutions (United States) and GlaxoSmithKline (United Kingdom) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"New Product Launches To Flourish Mumps Vaccine Market " is seen as one of major influencing trends for Mumps Vaccine Market during projected period 2021-2027.
The Mumps Vaccine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Mumps Vaccine Market Report?

Have a Query? Click Here

Other Related Reports

Vulvodynia Treatment Comprehensive Study by Application (Hospitals, Clinics, Others), Drugs (Local Anesthetics, Topical Estrogen, Tricyclic Antidepressants, Anticonvulsants, Nerve Blocks, Serotonin-N...
$ 3650
Atomic Emission Spectroscopy Comprehensive Study by Type (Flame Emission Spectroscopy, Plasma Emission Spectroscopy), Application (Foods And Drinks, Pharmaceutical Samples, Environmental Samples, Her...
$ 3800
Wound Management Products Comprehensive Study by Type (Adhesive Dressings, Gauze, Non-Adherent Dressings, Hydrogels, Wound Therapy Devices), Application (Hospitals, Specialty Clinics, Home Healthcare...
$ 3750
Veterinary X-ray Comprehensive Study by Type (Digital X-ray, Analog X-ray  ), Application (Orthopedics and Trauma, Oncology, Dental Applications), Technology (Direct (Capture) Radiography Systems, Co...
$ 3750
Growth Medium Comprehensive Study by Type (Classical Media, Stem Cell Media, Lysogeny Broth, Chemically Defined Media, Specialty Media, Serum-free Media, Others), Application (Cancer Research, Biopha...
$ 3750
Skin Biopsy Comprehensive Study by Disease Type (Skin Cancer, Actinic Keratosis, Dermatitis, Psoriasis, Fungal Infections, Eczema, Others), Techniques (Shave Biopsy, Punch Biopsy, Wedge Biopsy, Sauce...
$ 3800